| Efficacy and Safety of 10-Week or Shorter vs 12-Week or Longer Injection Intervals of Botulinum Toxin (NCT05103202) | University of Texas Southwestern Medical Center | 2021-11-04 |
| Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm (NCT05027997) | Addex Pharma S.A. | 2021-10-06 |
| Botulinum Toxin Relieves Anxiety, Depression and Sleep Disorderes in Patients With Blepharospasm (NCT04939909) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2021-07-12 |
| Effect of Non-psychoactive Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm (NCT04423341) | Silkiss Eye Surgery | 2020-05-20 |
| A Comparative Study of GPI's DBS and Pallidotomy in the Treatment of Meige Syndrome (NCT04618887) | Peking University People's Hospital | 2020-01-01 |
| Analysis of Gait Before and After Botulinum Toxin Treatment in Patients With Focal Dystonia (NCT03938363) | University Hospital, Grenoble | 2019-10-23 |
| Wumeiwan Jiawei Fang Use in Patients With Blepharospasm (NCT05618470) | China Academy of Chinese Medical Sciences | 2018-01-12 |
| Photic Blink Reflex in People With Blepharospasm and Increased Blinking (NCT03263000) | National Institute of Neurological Disorders and Stroke (NINDS) | 2017-10-30 |
| HLA Screening in Reducing the Risk of Antiepileptic Drug-induced Cutaneous Adverse Reactions (NCT03184597) | Second Affiliated Hospital of Guangzhou Medical University | 2017-08-01 |
| Safety and Efficacy of NABOTA in Treatment of Essential Blepharospasm (NCT02947815) | Daewoong Pharmaceutical Co. LTD. | 2016-10-01 |
| Blepharospasm Tools (NCT02780336) | Emory University | 2016-08-01 |
| Two Different Surgical Methods of Blepharospasm (NCT02765113) | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | 2016-05-01 |
| A Retrospective Chart Review of BOTOX® and Xeomin® for the Management of Cervical Dystonia and Blepharospasm (NCT02245958) | Allergan | 2015-08-01 |
| An RCT of a Patient-initiated Treatment Service for BEB and HFS (NCT02577224) | Moorfields Eye Hospital NHS Foundation Trust | 2015-08-01 |
| Pretarsal Versus Preseptal Botulinum Toxin for Patients With Eyelid Spasm (NCT03508882) | The University of Hong Kong | 2015-07-01 |
| Comparison of Different Botulinum Toxin A Injection Patterns in the Treatment of Blepharospasm (NCT02327728) | YangHui | 2013-02-01 |
| A Retrospective Chart Review of BOTOX® and Xeomin® for the Treatment of Cervical Dystonia and Blepharospasm (NCT01814774) | Allergan | 2013-01-01 |
| Blepharospasm Patient Survey for Patients With Blepharospasm (NCT01686061) | Merz Pharmaceuticals GmbH | 2012-09-01 |
| Testing the Effect of Zinc Supplementation to Improve the Treatment Effect of Botulinum Toxin for Oculofacial Spasm (NCT01546805) | St. Joseph's Healthcare Hamilton | 2012-04-01 |
| A Mechanical Device for Blepharospasm (NCT03269123) | Oxford University Hospitals NHS Trust | 2010-03-02 |
| MDs on Botox Utility (MOBILITY) (NCT00535938) | Allergan | 2007-09-01 |
| Blepharospasm Short Interval (NCT00507637) | Merz Pharmaceuticals GmbH | 2007-08-01 |
| Brain Changes in Blepharospasm (NCT00500799) | National Institute of Neurological Disorders and Stroke (NINDS) | 2007-07-09 |
| IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm (NCT00406367) | Merz Pharmaceuticals GmbH | 2006-10-01 |
| Comparison of Two Botulinum Type A Products in the Treatment of Blepharospasm (NCT00761592) | Allergan | 2006-07-01 |
| Brain Stimulation to Treat Blepharospasm or Meige Syndrome (NCT00411255) | National Institute of Neurological Disorders and Stroke (NINDS) | 2006-06-22 |
| Comparison of Korean Botulinum Toxin Type A Versus Botox in the Treatment of Essential Blepharospasm (NCT00682760) | Pacific Pharmaceuticals | 2005-10-01 |
| Post Marketing Surveillance Study of Dysport (NCT00210431) | Ipsen | 2004-10-01 |
| Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm (NCT00234507) | Ipsen | 2003-01-01 |
| Mexiletine for the Treatment of Focal Dystonia (NCT00001784) | National Institute of Neurological Disorders and Stroke (NINDS) | 1998-07-01 |